Dr Lal PathLabs beats in Q1; ICICI lifts target to Rs 1,690 but cuts rating to Hold
Patient volumes rose 8.2% year on year and sample volumes grew 10.7%, while revenue per patient increased about 10%. ICICI Securities lifted FY27 and FY28 earnings estimates and raised its target price, but downgraded the stock on valuation concerns.
Dr Lal PathLabs beat Q1 FY27 expectations as network additions, specialised tests and CGHS pricing lifted volumes and revenue per patient. ICICI Securities raised FY27/28 earnings estimates and its target price, but downgraded the stock to Hold.
Why this matters
No related recent Dr Lal PathLabs signals are available. The Q1 beat combines volume growth with higher revenue per patient, while ICICI's Hold rating indicates valuation caution despite raised earnings forecasts and target price.
retail-company signals are accelerating, up +567600% QoQ.